168 related articles for article (PubMed ID: 32725772)
1. Associations between muscle measures, survival, and toxicity in patients with limited stage small cell lung cancer.
Halvorsen TO; Valan CD; Slaaen M; Grønberg BH
J Cachexia Sarcopenia Muscle; 2020 Oct; 11(5):1283-1290. PubMed ID: 32725772
[TBL] [Abstract][Full Text] [Related]
2. Associations between severe co-morbidity and muscle measures in advanced non-small cell lung cancer patients.
Grønberg BH; Valan CD; Halvorsen T; Sjøblom B; Jordhøy MS
J Cachexia Sarcopenia Muscle; 2019 Dec; 10(6):1347-1355. PubMed ID: 31385663
[TBL] [Abstract][Full Text] [Related]
3. Skeletal muscle radiodensity is prognostic for survival in patients with advanced non-small cell lung cancer.
Sjøblom B; Grønberg BH; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Clin Nutr; 2016 Dec; 35(6):1386-1393. PubMed ID: 27102408
[TBL] [Abstract][Full Text] [Related]
4. The association between skeletal muscle measures and chemotherapy-induced toxicity in non-small cell lung cancer patients.
de Jong C; Chargi N; Herder GJM; van Haarlem SWA; van der Meer F; van Lindert ASR; Ten Heuvel A; Brouwer J; de Jong PA; Devriese LA; Huitema ADR; Egberts TCG; de Bree R; Deneer VHM
J Cachexia Sarcopenia Muscle; 2022 Jun; 13(3):1554-1564. PubMed ID: 35301821
[TBL] [Abstract][Full Text] [Related]
5. Effects of thoracic radiotherapy timing and duration on progression-free survival in limited-stage small cell lung cancer.
Zhao S; Zhou T; Ma S; Zhao Y; Zhan J; Fang W; Yang Y; Hou X; Zhang Z; Chen G; Zhang Y; Huang Y; Zhang L
Cancer Med; 2018 Sep; 7(9):4208-4216. PubMed ID: 30019533
[TBL] [Abstract][Full Text] [Related]
6. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation
with Concurrent Twice-daily Radiotherapy for Patients
with Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
[TBL] [Abstract][Full Text] [Related]
7. Shifting from hypofractionated to "conventionally" fractionated thoracic radiotherapy: a single institution's 10-year experience in the management of limited-stage small-cell lung cancer using concurrent chemoradiation.
Videtic GM; Truong PT; Dar AR; Yu EW; Stitt LW
Int J Radiat Oncol Biol Phys; 2003 Nov; 57(3):709-16. PubMed ID: 14529775
[TBL] [Abstract][Full Text] [Related]
8. Hypo- or conventionally fractionated radiotherapy combined with chemotherapy in patients with limited stage small cell lung cancer.
Zhang J; Fan M; Liu D; Zhao KL; Wu KL; Zhao WX; Zhu ZF; Fu XL
Radiat Oncol; 2017 Mar; 12(1):51. PubMed ID: 28283034
[TBL] [Abstract][Full Text] [Related]
9. Comorbidity and outcomes of concurrent chemo- and radiotherapy in limited disease small cell lung cancer.
Halvorsen TO; Sundstrøm S; Fløtten Ø; Brustugun OT; Brunsvig P; Aasebø U; Bremnes RM; Kaasa S; Grønberg BH
Acta Oncol; 2016 Nov; 55(11):1349-1354. PubMed ID: 27549509
[TBL] [Abstract][Full Text] [Related]
10. Treatment Outcomes of Older Participants in a Randomized Trial Comparing Two Schedules of Twice-Daily Thoracic Radiotherapy in Limited-Stage SCLC.
Killingberg KT; Grønberg BH; Slaaen M; Kirkevold Ø; Halvorsen TO
J Thorac Oncol; 2023 Jun; 18(6):803-812. PubMed ID: 36716960
[TBL] [Abstract][Full Text] [Related]
11. Cisplatin and etoposide chemotherapy combined with early concurrent twice-daily thoracic radiotherapy for limited-disease small cell lung cancer in elderly patients.
Okamoto K; Okamoto I; Takezawa K; Tachibana I; Fukuoka M; Nishimura Y; Nakagawa K
Jpn J Clin Oncol; 2010 Jan; 40(1):54-9. PubMed ID: 19837690
[TBL] [Abstract][Full Text] [Related]
12. Phase III study of concurrent versus sequential thoracic radiotherapy in combination with cisplatin and etoposide for limited-stage small-cell lung cancer: results of the Japan Clinical Oncology Group Study 9104.
Takada M; Fukuoka M; Kawahara M; Sugiura T; Yokoyama A; Yokota S; Nishiwaki Y; Watanabe K; Noda K; Tamura T; Fukuda H; Saijo N
J Clin Oncol; 2002 Jul; 20(14):3054-60. PubMed ID: 12118018
[TBL] [Abstract][Full Text] [Related]
13. The impact of body composition parameters on severe toxicities in patients with locoregionally advanced nasopharyngeal carcinoma undergoing neoadjuvant chemotherapy.
Xing X; Zhou X; Yang Y; Li Y; Hu C; Shen C
Ann Transl Med; 2021 Jul; 9(14):1180. PubMed ID: 34430621
[TBL] [Abstract][Full Text] [Related]
14. Muscle radiodensity loss during cancer therapy is predictive for poor survival in advanced endometrial cancer.
Lee J; Lin JB; Wu MH; Jan YT; Chang CL; Huang CY; Sun FJ; Chen YJ
J Cachexia Sarcopenia Muscle; 2019 Aug; 10(4):814-826. PubMed ID: 31094101
[TBL] [Abstract][Full Text] [Related]
15. Muscle loss during primary debulking surgery and chemotherapy predicts poor survival in advanced-stage ovarian cancer.
Huang CY; Yang YC; Chen TC; Chen JR; Chen YJ; Wu MH; Jan YT; Chang CL; Lee J
J Cachexia Sarcopenia Muscle; 2020 Apr; 11(2):534-546. PubMed ID: 31999069
[TBL] [Abstract][Full Text] [Related]
16. Pilot study of concurrent etoposide and cisplatin plus accelerated hyperfractionated thoracic radiotherapy followed by irinotecan and cisplatin for limited-stage small cell lung cancer: Japan Clinical Oncology Group 9903.
Kubota K; Nishiwaki Y; Sugiura T; Noda K; Mori K; Kawahara M; Negoro S; Watanabe K; Imamura F; Tamura T; Saijo N
Clin Cancer Res; 2005 Aug; 11(15):5534-8. PubMed ID: 16061870
[TBL] [Abstract][Full Text] [Related]
17. [A Phase I/II Study of Chemotherapy Concurrent with Twice-daily Radiotherapy
Schedules by Intensity Modulated Radiation Therapy Using Simultaneous Integrated Boost for Limited-stage Small Cell Lung Cancer].
You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):28-34. PubMed ID: 28103970
[TBL] [Abstract][Full Text] [Related]
18. Etoposide and cisplatin versus irinotecan and cisplatin in patients with limited-stage small-cell lung cancer treated with etoposide and cisplatin plus concurrent accelerated hyperfractionated thoracic radiotherapy (JCOG0202): a randomised phase 3 study.
Kubota K; Hida T; Ishikura S; Mizusawa J; Nishio M; Kawahara M; Yokoyama A; Imamura F; Takeda K; Negoro S; Harada M; Okamoto H; Yamamoto N; Shinkai T; Sakai H; Matsui K; Nakagawa K; Shibata T; Saijo N; Tamura T;
Lancet Oncol; 2014 Jan; 15(1):106-13. PubMed ID: 24309370
[TBL] [Abstract][Full Text] [Related]
19. Etoposide plus cisplatin followed by concurrent chemo-radiotherapy and irinotecan plus cisplatin for patients with limited-stage small cell lung cancer: A multicenter phase II study.
Xenidis N; Kotsakis A; Kalykaki A; Christophyllakis Ch; Giassas S; Kentepozidis N; Polyzos A; Chelis L; Vardakis N; Vamvakas L; Georgoulias V; Kakolyris S
Lung Cancer; 2010 Jun; 68(3):450-4. PubMed ID: 19783319
[TBL] [Abstract][Full Text] [Related]
20. A comparison of CT based measures of skeletal muscle mass and density from the Th4 and L3 levels in patients with advanced non-small-cell lung cancer.
Grønberg BH; Sjøblom B; Wentzel-Larsen T; Baracos VE; Hjermstad MJ; Aass N; Bremnes RM; Fløtten Ø; Bye A; Jordhøy M
Eur J Clin Nutr; 2019 Jul; 73(7):1069-1076. PubMed ID: 30254241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]